Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

Ilya Kister; Ryan Curtin; Amanda L. Piquet; Tyler Borko; Jinglan Pei; Barbara L Banbury; Tamar E. Bacon; Angie Kim; Michael Tuen; Yogambigai Velmurugu; Samantha Nyovanie; Sean Selva; Marie I. Samanovic; Mark J. Mulligan; Yury Patskovsky; Jessica Priest; Mark Cabatingan; Ryan C. Winger; Michelle Krogsgaard; Gregg J. Silverman

doi:10.1101/2024.01.23.24301671

Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

View ORCID ProfileIlya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard, Gregg J. Silverman

doi: https://doi.org/10.1101/2024.01.23.24301671

Ilya Kister

1NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Ilya Kister
For correspondence: ilya.kister{at}nyulangone.org michelle.krogsgaard{at}nyulangone.org gregg.silverman{at}nyulangone.org

Ryan Curtin

2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amanda L. Piquet

3Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tyler Borko

3Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jinglan Pei

4Genentech, Inc., South San Francisco, CA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Barbara L Banbury

5Adaptive Biotechnologies, Seattle, WA, USA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tamar E. Bacon

1NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Angie Kim

1NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Tuen

6NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yogambigai Velmurugu

2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Samantha Nyovanie

2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY

MPhil

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sean Selva

3Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, CO

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marie I. Samanovic

6NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, NY

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark J. Mulligan

6NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yury Patskovsky

2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jessica Priest

4Genentech, Inc., South San Francisco, CA

PharmD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark Cabatingan

4Genentech, Inc., South San Francisco, CA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ryan C. Winger

4Genentech, Inc., South San Francisco, CA

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michelle Krogsgaard

2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, NY

PhD

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gregg J. Silverman

7Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Supplemental Table S1 and Figure S1[supplements/301671_file14.docx]
Supplemental Table S2[supplements/301671_file15.pdf]

View the discussion thread.

PreviousNext

Posted January 24, 2024.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination

Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard, Gregg J. Silverman

medRxiv 2024.01.23.24301671; doi: https://doi.org/10.1101/2024.01.23.24301671

Share This Article: